Table 4.
Gene abundance of injured nerve ligand mRNAs in the neonatal nerve scRNA-seq dataset
| Gene abundance (%) | ||||||
|---|---|---|---|---|---|---|
| Gene | Epineurial | Endoneurial/perineurial | VSM/pericytes | Endothelial | Schwann cells | Immune cells |
| Adm** | 5.1 | 4.7 | BT | 3.0 | BT | BT |
| Agt* | 2.5 | BT | 12.2 | BT | BT | BT |
| Angpt1* | 5.1 | BT | 11.1 | BT | BT | BT |
| Angpt2* | 5.5 | BT | 18.1 | 6.9 | 2.0 | BT |
| Apln | BT | BT | BT | 29.0 | BT | BT |
| Bdnf | BT | BT | 3.6 | BT | BT | BT |
| Bmp1** | 34.2 | 21.5 | 10.9 | 11.0 | 10.8 | BT |
| Bmp2 | BT | BT | 6.7 | 3.4 | BT | 8.7 |
| Bmp4* | 3.4 | BT | BT | 6.9 | BT | BT |
| Bmp5 | BT | BT | 13.4 | BT | BT | BT |
| Bmp7** | BT | 3.9 | BT | BT | BT | BT |
| Ccl11** | 9.4 | 49.8 | 20.0 | BT | BT | 2.6 |
| Ccl2* | BT | 10.0 | 9.9 | BT | BT | 20.0 |
| Ccl24 | BT | BT | BT | BT | BT | 27.0 |
| Ccl3 | BT | BT | BT | BT | BT | 16.5 |
| Ccl5 | BT | BT | BT | BT | BT | 2.6 |
| Ccl7** | 3.4 | 18.5 | 2.7 | BT | BT | 14.8 |
| Ccl9 | BT | BT | BT | BT | BT | 28.7 |
| Clcf1 | BT | BT | BT | 2.3 | BT | BT |
| Csf1** | 15.2 | 4.3 | 4.8 | 4.1 | 2.4 | BT |
| Ctgf* | 7.1 | 4.0 | 7.4 | 7.4 | BT | BT |
| Cxcl1* | BT | 12.4 | 20.6 | 2.5 | BT | 2.6 |
| Cxcl10 | BT | BT | BT | BT | 2.6 | BT |
| Cxcl12** | 18.9 | 37.2 | 23.1 | 33.8 | BT | BT |
| Cxcl16 | BT | BT | BT | 4.2 | BT | 11.3 |
| Cxcl2 | BT | BT | BT | BT | BT | 4.3 |
| Cxcl9** | BT | 2.1 | BT | BT | BT | BT |
| Dhh | BT | BT | 2.3 | 7.1 | 25.6 | 3.5 |
| Dll1 | BT | BT | BT | 5.3 | BT | BT |
| Dll4 | BT | BT | BT | 15.2 | BT | BT |
| Ebi3 | BT | BT | BT | BT | BT | 13.0 |
| Eda** | 7.1 | 9.0 | BT | BT | 4.4 | BT |
| Edn3** | 4.1 | 3.5 | BT | BT | BT | BT |
| Efna1* | 3.1 | 4.3 | BT | 34.0 | BT | BT |
| Efna2** | 2.9 | 3.3 | BT | BT | 2.9 | BT |
| Efna4** | 2.6 | 3.6 | BT | BT | BT | BT |
| Efna5** | 6.0 | 4.0 | BT | BT | 2.3 | BT |
| Efnb1** | 18.3 | 30.6 | 6.3 | 9.7 | 9.1 | 2.6 |
| Efnb2** | 5.4 | 15.1 | 4.8 | 16.3 | BT | BT |
| Fgf1** | 5.1 | 5.6 | 3.6 | BT | 5.4 | 3.5 |
| Fgf10** | 5.7 | BT | BT | BT | BT | BT |
| Fgf18** | 7.8 | BT | BT | BT | BT | BT |
| Fgf7** | 21.0 | 10.3 | BT | BT | BT | BT |
| Figf** | 3.8 | 4.8 | BT | BT | BT | BT |
| Fstl1** | 96.0 | 92.2 | 72.9 | 59.3 | 43.0 | 11.3 |
| Gas6* | 22.4 | 14.3 | 7.4 | 24.6 | BT | 45.2 |
| Gdf10** | 8.4 | BT | BT | BT | BT | BT |
| Gdf11** | BT | 6.6 | 3.8 | 2.7 | BT | BT |
| Gmfb** | 9.5 | 17.6 | 6.1 | 13.8 | 14.1 | 9.6 |
| Gmfg | BT | BT | BT | 6.4 | BT | 36.5 |
| Grp | BT | BT | BT | 2.1 | BT | BT |
| Hbegf* | BT | 2.5 | 14.3 | 15.0 | 19.2 | 3.5 |
| Igf1** | 56.0 | 52.0 | 4.6 | 16.6 | 2.0 | 40.0 |
| Igf2** | 92.3 | 89.5 | 54.0 | 69.7 | 11.1 | 25.2 |
| Il15 | BT | BT | BT | BT | BT | 4.3 |
| Il16 | BT | BT | BT | 4.6 | BT | 12.2 |
| Il18 | BT | BT | BT | BT | BT | 9.6 |
| Il1b | BT | BT | BT | BT | BT | 3.5 |
| Il33** | 13.7 | 16.1 | BT | BT | BT | BT |
| Inha** | 2.6 | BT | BT | BT | BT | BT |
| Inhba** | 4.1 | BT | BT | BT | BT | BT |
| Inhbb | BT | BT | 8.0 | BT | BT | BT |
| Jag1** | 18.4 | 19.1 | 15.5 | 11.0 | BT | BT |
| Jag2 | BT | BT | BT | 7.1 | BT | BT |
| Ltb | BT | BT | BT | BT | BT | 2.6 |
| Mdk** | 52.3 | 68.1 | 20.2 | 8.8 | 20.9 | 8.7 |
| Metrn* | 3.4 | 8.7 | 10.5 | 5.0 | 43.2 | 10.4 |
| Mif* | 17.5 | 26.4 | 28.8 | 26.0 | 32.8 | 26.1 |
| Nenf** | 54.3 | 54.6 | 39.7 | 28.8 | 24.5 | BT |
| Ngf** | BT | 8.7 | 8.0 | BT | BT | 0.0 |
| Nov** | 23.8 | 4.3 | 3.8 | 3.4 | 2.8 | 3.5 |
| Nppc** | BT | 6.1 | BT | BT | BT | BT |
| Ntf3 | BT | BT | 2.3 | BT | BT | BT |
| Ntn1** | 22.2 | 10.0 | BT | BT | BT | BT |
| Osm | BT | BT | BT | BT | BT | 3.5 |
| Pdgfa* | 3.4 | 3.6 | 30.5 | 3.0 | 17.8 | BT |
| Pdgfb | BT | BT | 2.9 | 21.9 | BT | BT |
| Pdgfc | BT | BT | 3.2 | BT | 2.2 | 2.6 |
| Pf4 | BT | BT | BT | BT | BT | 61.7 |
| Pgf | BT | BT | 3.8 | BT | BT | BT |
| Pthlh** | 7.1 | 4.0 | BT | BT | BT | BT |
| Ptn* | 29.3 | 13.9 | 6.5 | 15.9 | 43.4 | 4.3 |
| Rspo1** | 7.8 | 6.5 | BT | BT | BT | BT |
| Rtn4* | 31.0 | 38.2 | 35.7 | 40.4 | 26.8 | 38.3 |
| Sema3b* | 5.4 | 6.5 | 2.3 | 2.8 | 34.7 | 7.8 |
| Sema3c** | 51.7 | 19.2 | BT | BT | 7.1 | 3.5 |
| Sema3d** | 10.4 | 15.9 | BT | BT | BT | BT |
| Sema3f* | 2.6 | BT | BT | 2.8 | BT | BT |
| Sema3g | BT | BT | BT | 9.6 | 7.5 | BT |
| Sema4a | BT | BT | BT | BT | BT | 10.4 |
| Sema4b | BT | BT | BT | BT | BT | 3.5 |
| Sema4c* | 5.1 | 5.7 | 2.7 | 8.1 | 8.5 | 5.2 |
| Sema4d | BT | BT | BT | BT | BT | 7.8 |
| Sema5a* | 5.4 | 5.5 | 12.4 | BT | BT | BT |
| Sema5b* | 4.4 | 8.6 | 14.1 | BT | 2.6 | BT |
| Sema6a* | 4.4 | 7.9 | BT | 22.8 | 4.5 | BT |
| Sema6b | BT | BT | BT | 2.5 | BT | BT |
| Sema6c** | 4.9 | 3.3 | 2.5 | BT | BT | BT |
| Sema6d* | 2.0 | 3.0 | 4.4 | 6.4 | 16.7 | 8.7 |
| Sema7a | BT | BT | 2.1 | 17.3 | 2.0 | BT |
| Sfrp1** | 50.5 | 48.5 | 2.9 | 4.1 | 28.0 | 3.5 |
| Sfrp2** | 17.2 | BT | BT | BT | BT | BT |
| Sfrp4** | 43.7 | 5.5 | BT | BT | BT | 2.6 |
| Sfrp5** | 5.4 | 30.7 | BT | BT | 8.1 | 2.6 |
| Tgfb1 | BT | BT | BT | 10.3 | BT | 20.9 |
| Tgfb2* | 12.1 | 2.7 | 18.3 | 9.9 | BT | BT |
| Tgfb3** | 21.5 | 8.3 | 10.9 | BT | BT | BT |
| Tnf | BT | BT | BT | BT | BT | 6.1 |
| Tnfrsf11b* | 2.9 | BT | BT | 3.9 | BT | BT |
| Tnfsf10 | BT | BT | BT | 6.4 | BT | BT |
| Tnfsf12** | 8.0 | 10.8 | 5.5 | 6.5 | 3.2 | 4.3 |
| Tnfsf9 | BT | BT | BT | BT | BT | 4.3 |
| Tslp | BT | BT | 2.7 | 2.8 | BT | 3.5 |
| Vegfa** | 16.0 | 3.6 | 3.8 | 3.2 | BT | BT |
| Vegfb** | 4.0 | 7.7 | 6.3 | 5.5 | 4.3 | 6.1 |
| Vegfc | BT | BT | BT | 8.5 | BT | BT |
| Wnt11 | BT | BT | 2.7 | BT | BT | BT |
| Wnt2** | 7.5 | BT | BT | BT | BT | BT |
| Wnt5a** | 17.0 | 6.8 | BT | BT | BT | BT |
The neonatal nerve scRNA-seq dataset (Fig. 2E) was analyzed to determine the percentage of cells within a given cell type that detectably expressed (≥2%) the 143 injured nerve ligand mRNAs (Table 2). Cell populations were defined as for the injured nerve analysis. BT = below threshold and indicates that <2% of cells detectably expressed the ligand mRNA. Ligands annotated with one asterisk in the leftmost column were expressed in ≥2% Pdgfra-positive mesenchymal cells and two asterisks indicate ligands with the highest expression in either the epineurial/perineurial or endoneurial Pdgfra-positive mesenchymal cells.
* >2% expression in Pdgfra-positive cells.
** >2% expression and highest expression in Pdgfra-positive cells.